Related Experiment Video

Updated: Jun 14, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation

Jung-Sun Kim1, Jaedeok Kim, Donghoon Choi

  • 1Division of Cardiology, Yonsei Cardiovascular Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

JACC. Cardiovascular Interventions
|March 20, 2010
PubMed

Insights

High-dose atorvastatin before percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) did not reduce major adverse cardiac events (MACEs). However, it improved immediate coronary blood flow, suggesting benefits for microvascular perfusion.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Previous studies show statin pre-treatment reduces MACEs in stable angina and ACS.
  • No prior randomized trials evaluated high-dose statins in STEMI patients undergoing primary PCI.

Purpose of the Study:

  • To assess the efficacy of high-dose atorvastatin pre-treatment in STEMI patients undergoing primary PCI.
  • To compare 80-mg vs. 10-mg atorvastatin pre-treatment efficacy on MACE and coronary flow parameters.

Main Methods:

  • 171 STEMI patients randomized to 80-mg (n=86) or 10-mg (n=85) atorvastatin pre-PCI.
  • All patients received clopidogrel 600 mg pre-PCI and atorvastatin 10 mg post-PCI.
  • Primary endpoint: 30-day MACE (death, MI, TVR). Secondary endpoints: TIMI frame count, myocardial blush grade, ST resolution.

Main Results:

  • MACE occurred in 5.8% (80mg) vs. 10.6% (10mg) (p=0.26).
  • 80-mg atorvastatin group showed significantly lower corrected TIMI frame count (p=0.01).
  • Higher myocardial blush grade (p=0.02) and ST-segment resolution (p=0.01) in the 80-mg arm.

Conclusions:

  • High-dose atorvastatin pre-treatment did not significantly reduce 30-day MACE in STEMI patients undergoing primary PCI.
  • High-dose atorvastatin improved immediate coronary flow, indicated by better TIMI frame count, blush grade, and ST resolution.
  • High-dose atorvastatin may optimize outcomes in STEMI patients by enhancing microvascular myocardial perfusion post-PCI.
Abstract

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...